Resources

Selected Filters:

Drug discovery > Pre-Clinical Development Clear Filters

White Papers

CNS drug development

9 Jan 2023

White Papers

Five criteria to use when selecting a CRO for a gene therapy study

9 Jan 2023

White Papers

Human AME (mass balance) studies

9 Jan 2023

White Papers

Selecting the location of a phase I clinical trial site for EU registration

9 Jan 2023

White Papers

Pharmacokinetic studies in patients

9 Jan 2023

White Papers

Plasma protein binding

9 Jan 2023

White Papers

RNAi therapeutics

9 Jan 2023

White Papers

Three lessons to help accelerate pharmaceutical breakthroughs for CNS disorders

9 Jan 2023

White Papers

Regulatory considerations in gene and cellular therapy development

9 Jan 2023

White Papers

Therapeutic oligonucleotide metabolite identification, profiling, and quantitation

9 Jan 2023

Resources

Resources Filter

Search

Selected Filters:

CNS drug development

Five criteria to use when selecting a CRO for a gene therapy study

Human AME (mass balance) studies

Selecting the location of a phase I clinical trial site for EU registration

Pharmacokinetic studies in patients

Plasma protein binding

RNAi therapeutics

Three lessons to help accelerate pharmaceutical breakthroughs for CNS disorders

Regulatory considerations in gene and cellular therapy development

Therapeutic oligonucleotide metabolite identification, profiling, and quantitation

Resources

Resources FilterResources Filter

Search

Selected Filters:

CNS drug development

Five criteria to use when selecting a CRO for a gene therapy study

Human AME (mass balance) studies

Selecting the location of a phase I clinical trial site for EU registration

Pharmacokinetic studies in patients

Plasma protein binding

RNAi therapeutics

Three lessons to help accelerate pharmaceutical breakthroughs for CNS disorders

Regulatory considerations in gene and cellular therapy development

Therapeutic oligonucleotide metabolite identification, profiling, and quantitation

Resources Filter